Prevalence of macrolide–lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents

Mendes, Rodrigo E.; Castanheira, Mariana; Farrell, David J.; Flamm, Robert K.; Sader, Hélio S.; Jones, Ronald N.

doi:10.1016/j.jgar.2016.08.013

Cited by 9 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common resistance element found was the macrolide efflux genetic assembly (MEGA) element with mef (E) [172]. In line with this, a multicenter study from 12 European countries in 2010-2013 found a 41% macrolide resistance rate among VGS, and 69% of the MR strains showed the M phenotype and 31% the MLS B phenotype [183]. Other non-European studies reported high macrolide resistance rates [148] in VGS collected from sterile sources (Korea 34%, USA 41%, Canada 38% and Northern Taiwan 40%) [178,184,185].…”

Section: Macrolide Resistance In Other Streptococcimentioning

confidence: 77%

An Overview of Macrolide Resistance in Streptococci: Prevalence, Mobile Elements and Dynamics

et al. 2022

View full text Add to dashboard Cite

Streptococcal infections are usually treated with beta-lactam antibiotics, but, in case of allergic patients or reduced antibiotic susceptibility, macrolides and fluoroquinolones are the main alternatives. This work focuses on studying macrolide resistance rates, genetic associated determinants and antibiotic consumption data in Spain, Europe and also on a global scale. Macrolide resistance (MR) determinants, such as ribosomal methylases (erm(B), erm(TR), erm(T)) or active antibiotic efflux pumps and ribosomal protectors (mef(A/E)-mrs(D)), are differently distributed worldwide and associated with different clonal lineages and mobile genetic elements. MR rates vary together depending on clonal dynamics and on antibiotic consumption applying selective pressure. Among Streptococcus, higher MR rates are found in the viridans group, Streptococcus pneumoniae and Streptococcus agalactiae, and lower MR rates are described in Streptococcus pyogenes. When considering different geographic areas, higher resistance rates are usually found in East-Asian countries and milder or lower in the US and Europe. Unfortunately, the availability of data varies also between countries; it is scarce in low- and middle- income countries from Africa and South America. Thus, surveillance studies of macrolide resistance rates and the resistance determinants involved should be promoted to complete global knowledge among macrolide resistance dynamics.

show abstract

Section: Macrolide Resistance In Other Streptococcimentioning

confidence: 77%

An Overview of Macrolide Resistance in Streptococci: Prevalence, Mobile Elements and Dynamics

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Abbreviations: MIC (minimum inhibitory concentration): Microgram per milliliter 20%, and in Iran, a Middle East country (2022), 48% of the isolates were identified as XDR (16,17). Excessive use of antibiotics has significantly increased the prevalence of bacterial skin infections, creating a serious health challenge (18,19).…”

Section: Discussionmentioning

confidence: 99%

The Glycopeptide-Susceptibility of Multidrug-Resistant/Extensively Drug-Resistant Staphylococcus aureus in Skin Infections

Hosseini,

Fozouni

2023

Middle East J Rehabil Health Stud

View full text Add to dashboard Cite

Background: The prevalence of drug-resistant Staphylococcus aureus is increasing alarmingly, limiting treatment options. Objectives: This study was conducted to investigate the minimum inhibitory concentration (MIC) of glycopeptides against multidrug-resistant (MDR) and extensively drug-resistant (XDR) S. aureus isolates from patients with skin infections. Methods: In this study, S. aureus isolates were collected from outpatients with skin infections (n = 250) during 2019 - 2022. The isolates were identified using routine microbiological and biochemical tests. Susceptibility to ten categories of antibacterial agents was assessed using the Kirby-Bauer method according to the Clinical and Laboratory Standards Institute M100 guidelines (2021). The MIC of glycopeptides was determined using the broth microdilution test. Results: Among methicillin-resistant S. aureus isolates (40.8%), the majority were from patients with impetigo (53.92%). The highest resistance rate was observed against penicillin (79.41%) and doxycycline (73.52%). Linezolid showed significant inhibitory properties against XDR (91%) and MDR (97%) S. aureus isolates (P = 0.01). The MIC of oritavancin that inhibited the growth of 90% of the MDR isolates (MIC90) was 2 µg/mL, which was eight times less than that of vancomycin (MIC90 = 16 µg/mL) and 16 times lower than that of teicoplanin (MIC90 = 32 µg/mL) in a manner that 91% of MDR isolates from impetigo were eliminated at concentrations 2 µg/mL. Oritavancin inhibited the growth of 54.5% of XDR isolates at MIC concentrations of ≥8 µg/mL. Conclusions: Considering the strong antibacterial activity of linezolid against MDR S. aureus isolates, this antibiotic can effectively treat skin infections caused by S. aureus and prevent the development of resistance to other antibiotics. In addition, considering the great inhibitory properties of oritavancin against MDR S. aureus strains, the efficacy of this agent for treating skin infections, particularly impetigo, should be investigated.

show abstract

“…Following this discovery several more enzymes have been found that show a similar activity. These MPHs all mediate the transfer of the γ-phosphate group from GTP onto the macrolide substrates and doing so confer resistance to a group of bacteria ranging from Gram-negative ( E. coli, Pseudomonas, Pasteurella, Klebsiella, Serratia, Shigella ) to Gram-positive ( Staphylococcus ) ( Matsuoka et al, 1998 , 2003 ; Nguyen et al, 2009 ; Ferjani et al, 2012 ; Mendes et al, 2017 ).…”

Section: Macrolide Phosphotransferasesmentioning

confidence: 99%

Look and Outlook on Enzyme-Mediated Macrolide Resistance

2018

View full text Add to dashboard Cite

Since their discovery in the early 1950s, macrolide antibiotics have been used in both agriculture and medicine. Specifically, macrolides such as erythromycin and azithromycin have found use as substitutes for β-lactam antibiotics in patients with penicillin allergies. Given the extensive use of this class of antibiotics it is no surprise that resistance has spread among pathogenic bacteria. In these bacteria different mechanisms of resistance have been observed. Frequently observed are alterations in the target of macrolides, i.e., the ribosome, as well as upregulation of efflux pumps. However, drug modification is also increasingly observed. Two classes of enzymes have been implicated in macrolide detoxification: macrolide phosphotransferases and macrolide esterases. In this review, we present a comprehensive overview on what is known about macrolide resistance with an emphasis on the macrolide phosphotransferase and esterase enzymes. Furthermore, we explore how this information can assist in addressing resistance to macrolide antibiotics.

show abstract

Prevalence of macrolide–lincosamide resistance and multidrug resistance phenotypes in streptococcal isolates causing infections in European hospitals: Evaluation of the in vitro activity of oritavancin and comparator agents

Cited by 9 publications

References 21 publications

An Overview of Macrolide Resistance in Streptococci: Prevalence, Mobile Elements and Dynamics

An Overview of Macrolide Resistance in Streptococci: Prevalence, Mobile Elements and Dynamics

The Glycopeptide-Susceptibility of Multidrug-Resistant/Extensively Drug-Resistant Staphylococcus aureus in Skin Infections

Look and Outlook on Enzyme-Mediated Macrolide Resistance

Contact Info

Product

Resources

About